Derma Sciences (DSCI -1.6%) says it's initiated patient enrollment in the first of two Phase 3...


Derma Sciences (DSCI -1.6%) says it's initiated patient enrollment in the first of two Phase 3 clinical trials for its investigational topical drug candidate DSC127. The two trials are designed to assess the safety and efficacy of DSC127 in chronic, non-healing diabetic foot ulcers and to support the filing of a New Drug Application with the FDA.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs